<DOC>
	<DOCNO>NCT01104558</DOCNO>
	<brief_summary>At present , clinical data different functional response beta-blockers associate beta-adrenergic receptor polymorphism . But data report , incidence beta-adrenergic receptor polymorphism association beta-adrenergic receptor polymorphism response beta-blocker therapy Korean heart failure ( HF ) subject . This single-arm , open-label , multicentric study design purpose analyze association genetic polymorphism beta-adrenergic receptor effect beta-blocker ( bisoprolol ) Korean HF subject .</brief_summary>
	<brief_title>Association Between Genetic Polymorphism Beta-adrenergic Receptor Effects Bisoprolol Korean Heart Failure Patients .</brief_title>
	<detailed_description>Heart failure impair quality life individual consider main cause morbidity mortality . Prognosis HF subject depend severity , age sex . Subjects HF require lifelong treatment . Pharmacological treatment aim improve quality life survival HF subject . OBJECTIVES : Primary objective : - To analyze association genetic polymorphism beta-adrenergic receptor effect beta-blocker ( bisoprolol ) Korean HF subject Secondary objective : - The frequency polymorphism beta adrenergic receptor Korean HF subject - To evaluate change baseline 6-minute walk test , heart rate ( HR ) , blood pressure ( BP ) , pro B-type natriuretic peptide ( BNP ) level week 26 End Treatment ( EOT ) - To compare frequency duration hospitalization due heart failure The method involve study follow : - Initial evaluation HF subject - Blood genomic deoxyribonucleic acid ( DNA ) isolation collection - Bisoprolol treatment add therapy standard treatment HF subject 6 month - Genotype beta adrenergic receptor polymorphism - Follow evaluation treat subject Bisoprolol give start dose 1.25 milligram ( mg ) daily two week well tolerate , dose increase 2.5 mg , 3.75 mg , 5 mg daily interval two week , 5 mg daily maintenance therapy . If subject tolerable , dose increase 10 mg/day maximum dose .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>&gt; 18 year age &lt; 80 year age Chronic heart failure subject stable clinical condition New York Heart Association ( NYHA ) functional classification IIIII Left ventricular ejection fraction ( LVEF ) â‰¤45 % NYHA functional classification IV Acute myocardial infarction , Unstable Angina Pectoris , Coronary artery bypass graft , Percutaneous coronary intervention ( PCI ) , Valve surgery precede 3 month Hypersensitivity bisoprolol Concor excipients Subjects mild valvular stenosis severe ( Grade III/IV ) pulmonary insufficiency Systolic Blood Pressure &lt; 90 millimeter mercury ( mmHg ) screen Resting Heart Rate &lt; 55 beat per minute ( bpm ) confirm electrocardiogram ( ECG ) screen Subjects take concomitant drug drugdrug interaction ( DDI ) bisoprolol Woman childbearing age without effective contraception measure , pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Bisoprolol</keyword>
	<keyword>Chronic Heart failure</keyword>
</DOC>